Table 2.
Health-related quality of life of patients with versus without prolonged CNSD use
| Prolonged CNSD use | |||
|---|---|---|---|
| No (n = 146) | Yes (n = 100) | p-value | |
| Dimensions of HRQoL, n (%) | |||
| Mobility | |||
| No problems in walking about | 60 (42) | 16 (17) | < 0.001 |
| Some problems in walking about | 59 (41) | 52 (54) | |
| Being confined to bed | 24 (17) | 28 (29) | |
| Self-care | |||
| No problems with self-care | 109 (76) | 50 (52) | < 0.001 |
| Some problems with self-care | 28 (20) | 40 (42) | |
| Being unable to wash or dress myself | 6 (4) | 6 (6) | |
| Usual activities | |||
| No problems with performing my usual activities | 77 (54) | 16 (17) | < 0.001 |
| Some problems with performing my usual activities | 45 (31) | 61 (63) | |
| Being unable to perform my usual activities | 21 (15) | 19 (20) | |
| Pain/discomfort | |||
| No pain or discomfort | 48 (34) | 19 (20) | 0.02 |
| Moderate pain or discomfort | 76 (53) | 53 (55) | |
| Extreme pain or discomfort | 19 (13) | 24 (25) | |
| Anxiety/depression | |||
| Not being anxious or depressed | 96 (67) | 40 (42) | < 0.001 |
| Being moderately anxious or depressed | 44 (31) | 47 (49) | |
| Being extremely anxious or depressed | 3 (2) | 9 (9) | |
| EQ VAS, mean (SD) | 62 (23) | 50 (17) | < 0.001 |
| Global score of HRQoL (EQ-5D index), median (IQR) | 0.73 (0.30 to 0.81) | 0.19 (0.002 to 0.69) | < 0.001 |
Abbreviations: CNSDs Central nervous system depressant drugs; VAS Visual analogue scale, SD Standard deviation, IQR Interquartile range